Lansoprazole
Proton Pump Inhibitors
Sold as PREVACID · PREVACID FASTAB · signature care acid…
- Drug class
- Proton Pump Inhibitors
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 70
- FDA reports (12 mo)
- 6,293
Overview
Plain-language summary, compiled from the cited regulatory records
Lansoprazole is a proton pump inhibitor [1]. It is approved for several uses in adults, including the treatment of active duodenal ulcers and active benign gastric ulcers [1]. Lansoprazole is also indicated for the healing of gastric ulcers associated with nonsteroidal anti-inflammatory drug (NSAID) use [1]. Additionally, it is used to reduce the risk of duodenal ulcer recurrence in adults when used for the eradication of H. pylori and for the maintenance of healed duodenal ulcers [1].
This medication is available under various brand names, including signature care acid reducer [1]. In the past 12 months, there have been 6,293 adverse event reports associated with lansoprazole [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 32 | May 22, 2026 |
| CA Canada | Health Canada | 27 | December 23, 2025 |
| US United States | FDA | 11 | January 16, 2026 |
GBUnited Kingdom· MHRA
32 products
Uses
• Treatment of duodenal and gastric ulcer • Treatment of reflux oesophagitis • Prophylaxis of reflux oesophagitis • Eradication of Helicobacter pylori (H. 2) requiring continued therapy • Symptomatic gastroesophageal reflux disease • Zollinger-Ellison syndrome.
How to take
CACanada· Health Canada
27 products
Uses
2 Recommended Dose and Dosage Adjustment) • Eradication of Helicobacter pylori (H. pylori) PRO-LANSOPRAZOLE, in combination with clarithromycin plus amoxicillin as triple therapy, is indicated for the treatment of patients with H. pylori infection and active duodenal ulcer disease.
Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS). 1 Pediatrics Pediatrics (1 to 17 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of PRO-LANSOPRAZOLE in pediatric patients has been established.
3 Pediatrics). PRO-LANSOPRAZOLE is indicated for treatment of erosive and non-erosive GERD in children, aged 1 to 17 years. The clinical trial treatment period did not extend beyond 12 weeks. 2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.
USUnited States· FDA
11 products
Uses
1 INDICATIONS AND USAGE Lansoprazole delayed-release capsules is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults. 1 ) Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults.
2 ) Maintenance of healed duodenal ulcers in adults. 3 ) Treatment of active benign gastric ulcer in adults. 4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. 5 ) Risk reduction of NSAID-associated gastric ulcer in adults.
6 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. 7 ) Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. 8 ) Maintenance of healing of EE in adults.
9 ) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. 1 ) ]. 2 Eradication of H. pylori to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole delayed-release capsules/amoxicillin/clarithromycin Lansoprazole delayed-release capsules in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with H.
Drug interactions
Known interactions involving Lansoprazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 595. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL232180099 · revised May 22, 2026
- [2]Health Canada (DPD) · 02366282 · revised December 23, 2025
- [3]FDA DailyMed · 18b4020f-d7e6-42… · revised January 16, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.